The current preventions of malaria are protection against mosquito bites and taking chemoprophylactic anti-malarial drugs.
Co-administration of ART with CHR in ratio of 1:2 achieved a synergic anti-malarial effect partly because of the noncompetitive or uncompetitive inhibition of CHR of drug-metabolism enzymes, especially CYP3A which is closely related to the auto-induction of ART.
It is critical to evaluate the safety of anti-malarial drugs being deployed in large, diverse populations.
As a result of this work, CYP 2D6 and MAO-A have been implicated as the key enzymes associated with PQ metabolism, and metabolites previously identified as potentially playing a role in efficacy and haemolytic toxicity have been attributed to production via CYP 2D6 mediated pathways.
Pharmacological pressure affects the resistance strains prevalence. As for SP, the disappearance of 436A and the decrease in 540 G suggest that these mutations are not fixed.
TaqMan Allelic Discrimination assay provides a good alternative tool in detection of SNPs associated with anti-malarial drug.
PCR analyses from multiple blood samples collected during the early treatment phase revealed a complex picture of parasite sub-populations.
Glucose is the primary source of energy and a key substrate for most cells.
Self-reported malaria was extremely common in this population and adherence to treatment guidelines for the management of malaria in pregnancy was poor.
Plasmodium falciparum msp1, msp2 and glurp markers were highly polymorphic with low allele frequencies. A total of 17 msp1 genotypes [eight MAD20-, one RO33- and eight K1-types]; 116 msp2 genotypes [83 3D7 and 33 FC27- types] and 14 glurp genotypes were recorded.